| Biovest Meets Skeptic's Requirements for 'The Next Dendreon' - Part 4 James Hill, MD submits: We’re looking at why Biovest (BVTI.PK) may qualify as “the next Dendreon” under standards biotech analyst David Miller describes in his May 12 Minyanville article. Dendreon’s (DNDN) prostate cancer vaccine, Provenge (sipuleucel-T), received FDA approval in April 2010, creating a paradigm shift in cancer treatment. In this series, Part 1 discussed vaccine manufacturing; Part 2 and Part 3, cancer vaccine technology.Complete Story » seekingalpha.com |
Cubist Pharmaceuticals vs. the Hatch-Waxman Act Jason Chew submits: In 2003, Cubist Pharmaceuticals (CBST) was granted approval for its novel antibiotic, Cubicin, for complicated skin and skin structure infections by Gram-positive bacteria, including drug-resistant strains. Over the next couple years, the stock doubled from about $10 to $20. The stock has languished in the $20 trading range for nearly five years now. There have been some pops and drops to be sure, but in general, the stock has barely budged.At the same time, revenues have grown quite nicely, exceeding even management’s expectations. In 2009, sales reached $562 million; it is expected to reach up to $650 million in 2010 and peak at $1 billion. Net income for 2009 was about $80 million and in fact, the company has been profitable since the third quarter of 2006. Cash flow is strong; the company currently has nearly $500 million in cash, with $245 million in debt.Complete Story » seekingalpha.com |
FDA Raises Concerns About Fibromyalgia Drug The FDA raised safety concerns about a proposed Jazz Pharmaceuticals drug to treat the pain disorder fibromyalgia, including the potential for misuse and abuse of the product. online.wsj.com |
Array BioPharma to Present at the UBS Global Life Sciences Conference [Business Wire] - BOULDER, Colo.----Array BioPharma Inc. today announced that its Chief Executive Officer, Robert E. Conway, will speak at the UBS Global Life Sciences Conference in New York City. The public is welcome to participate in the conference through a webcast on the Array BioPharma website. us.rd.yahoo.com |
Cochlear Implants Recalled Sonova is recalling hearing-aid implants made by its U.S. unit Advanced Bionics, a move that will hit sales and dent profits. Sonova shares slid. online.wsj.com |